Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022
This single-center, real-world analysis of 1,000 mBC patients revealed significant OS differences across molecular subtypes and provided valuable information on prognostic factors. These findings underscore the impact of tumor biology and the need for personalized treatment approaches.
Authors
- Dirk Jäger
- Patrick Ziegler
- Laura L. Michel (ORCID: https://orcid.org/0000-0002-7784-2826)
- Sara Y. Brucker (ORCID: https://orcid.org/0000-0001-5162-1542)
- Andreas Hartkopf
- Erik Belleville
- Matthias W. Beckmann (ORCID: https://orcid.org/0000-0002-8441-693X)
- Carlo Fremd (ORCID: https://orcid.org/0000-0002-7840-430X)
- Katharina Smetanay (ORCID: https://orcid.org/0000-0003-2881-5183)
- Sabrina Uhrig
- Verena Thewes
- Manuel Feißt (ORCID: https://orcid.org/0000-0002-5016-9731)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Christian Maurer (ORCID: https://orcid.org/0000-0003-4388-5163)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-1709-1079)
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- Zimmer Biomet (Germany) (DE)
- National Center for Tumor Diseases (DE)
- University Children's Hospital Tübingen (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Breast Care
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1159/000548610
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00